Gil M. Labrucherie Acquires 6,282 Shares of Septerna, Inc. (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie bought 6,282 shares of the stock in a transaction on Tuesday, February 25th. The stock was acquired at an average price of $5.59 per share, with a total value of $35,116.38. Following the completion of the acquisition, the chief financial officer now owns 36,282 shares of the company’s stock, valued at $202,816.38. This represents a 20.94 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Septerna Stock Performance

SEPN stock opened at $6.47 on Friday. The stock has a fifty day simple moving average of $16.08. Septerna, Inc. has a 1-year low of $4.17 and a 1-year high of $28.99.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC purchased a new position in shares of Septerna during the 4th quarter valued at $25,000. New York State Common Retirement Fund purchased a new position in shares of Septerna during the 4th quarter valued at $32,000. Legal & General Group Plc purchased a new position in shares of Septerna during the 4th quarter valued at $42,000. Summit Investment Advisors Inc. purchased a new position in shares of Septerna during the 4th quarter valued at $45,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Septerna during the 4th quarter valued at $52,000.

Analysts Set New Price Targets

SEPN has been the subject of several recent research reports. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price objective on shares of Septerna in a report on Tuesday, February 11th. JPMorgan Chase & Co. began coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price on the stock. Wells Fargo & Company cut Septerna from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $43.00 to $14.00 in a research report on Tuesday, February 18th. Finally, TD Cowen began coverage on Septerna in a research report on Tuesday, November 19th. They set a “buy” rating on the stock.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.